Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of treatment with ABX-EGF on best
overall objective response rate by modified RECIST (confirmed complete or partial response)
in Japanese subjects with metastatic colorectal cancer.